Table 3.

Multivariate Model (Multivariate 2) Examining Risk of Biochemical Disease Recurrence for Statin Users Compared With Nonusers Adjusting for Multiple Clinical and Pathological Variables

	Unadjusted HR (95% CI)	Unadjusted P	Adjusted HR (95% CI)	Adjusted P
Statin use	0.92 (0.67–1.25)	.57	0.70 (0.50–0.97)	.03
Age	1.00 (0.99–1.02)	.58	1.01 (0.99–1.03)	.30
Race (Ref = white)
Black	1.26 (1.00–1.58)	.05	1.13 (0.89–1.45)	.32
Nonwhite/nonblack	0.90 (0.56–1.45)	.66	1.12 (0.67–0.89)	.67
Center (Ref = Center 1)
Center 2	0.62 (0.41–0.94)	.02	0.57 (0.37–0.89)	.01
Center 3	0.96 (0.71–1.30)	.80	0.79 (0.56–1.11)	.18
Center 4	1.19 (0.92–1.56)	.19	0.90 (0.68–1.19)	.45
Biopsy Gleason (Ref: <6)
7	2.79 (2.18–3.56)	<.001	1.88 (1.43–2.47)	<.001
>7	3.89 (2.81–5.30)	<.001	2.21 (1.54–3.17)	<.001
Clinical stage	1.26 (1.00–1.57)	.04	1.09 (0.86–1.38)	.46
BMI (Ref: ≤24.9 kg/m2)
25.0–29.9 kg/m2	1.34 (0.99–1.81)	.06	1.38 (1.01–1.87)	.04
30.0–34.9 kg/m2	1.80 (1.29–2.51)	.001	1.91 (1.36–2.69)	<.001
≥35.0 kg/m2	1.79 (1.16–2.77)	.01	1.87 (1.19–2.94)	.01
PSAa	2.06 (1.75–2.41)	<.001	1.56 (1.30–1.87)	<.001
% cores positive	4.26 (2.78–6.53)	<.001	1.41 (0.86–2.32)	.17
Year of surgery	1.01 (0.97–1.05)	.62	1.00 (0.96–1.05)	.85
Pathology Gleason (Ref: <6)
7	3.55 (2.64–4.79)	<.001	1.82 (1.31–2.54)	<.001
>7	6.95 (4.85–9.94)	<.001	2.76 (1.82–4.18)	<.001
Extracapsular extension	2.42 (1.93–3.05)	<.001	1.23 (0.93–1.62)	.14
Seminal vesicle invasion	4.16 (3.13–5.53)	<.001	2.04 (1.46–2.85)	<.001
Positive margins	3.06 (2.43–3.86)	<.001	2.01 (1.56–2.58)	<.001
Lymph node invasion	4.21 (1.99–8.92)	<.001	0.90 (0.39–2.05)	.80

HR indicates hazard ratio; CI, confidence interval; BMI, body mass index; PSA, prostate-specific antigen.

^aPSA was logarithmically transformed.